MCRB News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

MC

Mkt Cap

$24.7M

Volume

36.58K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026Seres Therapeutics announced preclinical data for SER-428, an investigational live biotherapeutic designed to reduce bloodstream infections in critically ill patients. The novel oral liquid formulation showed up to 1,000-fold reduction of pathogenic bacteria in preclinical models and builds on positive results from SER-155. The company is designing a Phase 1b trial in collaboration with Columbia University, with further development pending funding.GlobeNewswire Inc. · Oct 15, 2026

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Seres Therapeutics granted stock options to purchase 4,200 shares to two new employees on September 4, 2026, with an exercise price of $5.72 per share under its 2022 Employment Inducement Award Plan. The options vest 25% on the first anniversary and 6.25% quarterly thereafter.GlobeNewswire Inc. · Sep 8, 2026

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026Seres Therapeutics announced three presentations at the 2026 ESCMID congress highlighting Phase 1b data for SER-155, a live biotherapeutic candidate. The data demonstrated that SER-155 induced significant and durable shifts in GI microbiome composition with improved epithelial barrier integrity, correlating with reduced bloodstream infections in allogeneic hematopoietic cell transplant patients. Additional presentations explored the role of live biotherapeutics in IBD and immunocompromised patients.GlobeNewswire Inc. · Apr 20, 2026

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesSeres Therapeutics reported a net income of $5.7 million for full year 2025 compared to a net loss of $125.8 million in 2024, primarily driven by gains from the VOWST sale to Nestlé and reduced operating expenses. The company is prioritizing development of SER-155 for immune checkpoint-related enterocolitis and SER-603 for inflammatory bowel disease, with clinical data from an investigator-sponsored trial expected in Q2 2026. With $45.8 million in cash, Seres expects to fund operations through Q3 2026 and is actively seeking partnerships and additional funding to advance its pipeline.GlobeNewswire Inc. · Mar 12, 2026

$3.25+ Bn Human Microbiome Market Trends and Global Forecasts, 2035, Driven by Advancements in Microbiome Sequencing, Rising Investments in R&D, and Increasing Demand for Personalized MedicineThe human microbiome market is expected to grow from $0.85 billion in 2026 to $3.27 billion by 2035, driven by advancements in sequencing technologies, rising R&D investments, and increasing demand for personalized medicine. Currently, approximately 215 microbiome therapeutics are in development across various stages, with over 50% in clinical stages. North America is expected to dominate the market, supported by regulatory approvals and strategic partnerships.GlobeNewswire Inc. · Feb 16, 2026

Seres (MCRB) Q3 2025 Earnings Call TranscriptSeres Therapeutics reported Q3 2025 earnings, highlighting progress on SER-155, a live biotherapeutic targeting bloodstream infections in stem cell transplant patients. The company secured a $3.6M CARB-X grant, reduced workforce by 25%, and is seeking additional capital to advance clinical trials.The Motley Fool · Nov 6, 2025

Denodo University Challenge Now Open: Data and AI for Real-World ImpactDenodo, a leader in data management, has announced the Denodo University Challenge, 'Data and AI for Real-World Impact', which aims to encourage students to develop innovative AI-driven solutions that have a demonstrable impact on social and economic challenges. The challenge will leverage Denodo's data management and AI tools, including the Denodo Platform and the Denodo AI SDK.GlobeNewswire Inc. · Jun 2, 2025

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual MeetingSeres Therapeutics presented new exploratory biomarker data from its SER-155 Phase 1b study, showing evidence of improved intestinal epithelial barrier integrity, modulation of systemic inflammatory responses, and potential to promote immune reconstitution after allogeneic hematopoietic stem cell transplant.GlobeNewswire Inc. · May 27, 2025

Microbiome Disease Pipeline Insight 2025: Over 180 Drugs in Development Across 140+ CompaniesThe Microbiome Disease Pipeline Report 2025 reveals 180+ drugs under development across 140+ companies, covering late-stage, mid-stage, and early-stage therapies. Major players such as MaaT Pharma, Seres Therapeutics, Biomica, and Vedanta Biosciences are advancing Phase III and II candidates targeting microbiome-related conditions.GlobeNewswire Inc. · Mar 21, 2025

Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsightThe microbiome disease pipeline is a robust space with 140+ active players working to develop 180+ pipeline microbiome disease drugs. Key companies like MaaT Pharma, Qu Biologics, Biomica Ltd., and Seres Therapeutics are evaluating new microbiome disease drugs to improve the treatment landscape.GlobeNewswire Inc. · Mar 4, 2025

MC

MCRBSeres Therapeutics, Inc.

MCRB

Pay with—

Available Balance0.00

Your PositionYou don't own any MCRB yet.

Related Tickers

Earnings